专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140235614A1 MONOCYCLIC PYRIDINE DERIVATIVE 有权
标题翻译：单环吡啶衍生物
公开(公告)号：US20140235614A1
公开(公告)日：2014-08-21
申请号：US14183864
申请日：2014-02-19
申请人： Eisai R&D Management Co., Ltd.
发明人： Setsuo Funasaka , Toshimi Okada , Keigo Tanaka , Satoshi Nagao , Isao Ohashi , Yoshinobu Yamane , Yusuke Nakatani , Yuki Karoji
IPC分类号： C07D409/14 , C07D401/14 , C07D401/12
CPC分类号： C07D409/14 , C07D401/12 , C07D401/14
摘要： The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.
摘要翻译：本发明提供了具有FGFR抑制活性的新化合物或其药学上可接受的盐，以及含有该化合物的药物组合物。具体地说，本发明提供由下式（I）表示的化合物或其药学上可接受的盐：其中n表示0〜2; A表示亚芳基或亚杂芳基; G表示单键，氧原子或-CH 2 - ; E表示含氮非芳族杂环; R1表示烷氧基等; R2表示氢原子等; 并且R 3表示氢原子，烷基，烷氧基等，条件是当E表示氮杂环丁烷环且R 2或R 3存在于氮杂环丁烷环上的氮原子上时，R 2或R 3不表示氢原子。

2. 发明授权

US08933099B2 Monocyclic pyridine derivative 有权
标题翻译：单环吡啶衍生物
公开(公告)号：US08933099B2
公开(公告)日：2015-01-13
申请号：US14183864
申请日：2014-02-19
申请人： Eisai R&D Management Co., Ltd.
发明人： Setsuo Funasaka , Toshimi Okada , Keigo Tanaka , Satoshi Nagao , Isao Ohashi , Yoshinobu Yamane , Yusuke Nakatani , Yuki Karoji
IPC分类号： A61K31/445 , C07D401/14 , C07D409/14 , C07D401/12
CPC分类号： C07D409/14 , C07D401/12 , C07D401/14
摘要： The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.
摘要翻译：本发明提供了具有FGFR抑制活性的新化合物或其药学上可接受的盐，以及含有该化合物的药物组合物。具体地说，本发明提供由下式（I）表示的化合物或其药学上可接受的盐：其中n表示0〜2; A表示亚芳基或亚杂芳基; G表示单键，氧原子或-CH 2 - ; E表示含氮非芳族杂环; R1表示烷氧基等; R2表示氢原子等; 并且R 3表示氢原子，烷基，烷氧基等，条件是当E表示氮杂环丁烷环且R 2或R 3存在于氮杂环丁烷环上的氮原子上时，R 2或R 3不表示氢原子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式